Q4 2025 ANI Pharmaceuticals Inc Earnings Call Transcript
Key Points
- ANI Pharmaceuticals Inc (ANIP) delivered record revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS in 2025, driven by strong performance across its rare disease and generics business units.
- The company achieved a 44% year-over-year growth in total revenues and a 47% increase in adjusted non-GAAP EBITDA for the full year 2025.
- Corticotropin, the lead rare disease asset, saw full-year revenues increase by 76% year over year, significantly expanding its reach in underpenetrated specialty indications.
- The generics business outperformed with a 28% year-over-year growth in 2025, supported by strong R&D and operational capabilities.
- ANI Pharmaceuticals Inc (ANIP) expects to deliver over $1 billion in revenue in 2026, representing a 23% growth over 2025, with rare disease accounting for approximately 60% of total revenues.
- Non-GAAP gross margin decreased by approximately 400 basis points in the fourth quarter of 2025 due to product mix, including significant growth of royalty-bearing products.
- The company anticipates a decrease in adjusted gross margin in 2026, driven by higher forecast sales of royalty-bearing products and lower brand sales.
- ANI Pharmaceuticals Inc (ANIP) faces typical seasonality challenges related to insurance re-verifications, impacting first-quarter revenues for Cortrophin gel.
- The company is experiencing delays in the re-verification process due to increased Cortrophin patient volume and weather-related physician office closures.
- The phase four trial results for Cortrophin gel in acute gouty arthritis flares will not be available by the mid-year launch of the new sales organization, potentially impacting immediate sales strategy.
Good day everyone and welcome to today's ANI Pharmaceuticals Inc. fourth quarter and full year 2025 earnings results call. (Operator Instructions). It is now my pleasure to turn the conference over to Courtney Mogerley. Please go ahead.
Thank you, Erica. Welcome to ANI Pharmaceuticals fourth quarter and full year 2025 earnings results call. This is Courtney Mogerley, investor relations for A&I.
With me on today's call are Nikhil Lalwani, President and Chief Executive Officer, Stephen Carey, senior Vice President and Chief Financial Officer, and Chris Mutz, senior Vice President and head of ANI's rare disease business.
You can also access the webcast of this call through the investors section of the AI website at anipharmaceuticals.com. This call is accompanied by a slide deck that can be accessed by going to the events section of the investors page of our website. You can turn to our forward-looking statements on slide two.
Before we begin, I would like
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
